Growth regulatory functions of Rb2/p130, which aim at a sustained arrest such as in quiescent or differentiated cells, qualify the protein also to act as a central regulator of growth arrest in cellular senescence. In this respect, Rb2/ p130 functions are connected to signaling pathways induced by p53, which is a master regulator in cellular senescence. Here, we summarize the pathways, which specify pRb2/p130 to control this arrest program and distinguish its functions from those of pRb/p105.
Introduction
Cellular senescence is defined as a terminal proliferative arrest which irreversibly stalls cells in G1 of the cell cycle (Hayflick, 1965) . Originally, this kind of growth arrest was described as a cellular response to shortening of telomeres, but now it is known to be induced by a variety of signals, such as inappropriate nucleotide pools, DNA damage, hyperproliferative signals triggered by oncogenes or loss of tumor suppressor proteins (Vaziri et al., 1997; Dimri et al., 2000; Campisi, 2001) . Senescent cells do not respond to mitogenic signals, display an altered gene expression profile, and exhibit senescence associated b-galactosidase (SA-b-gal) as a prominent phenotypic marker (Dimri et al., 1995) .
The program of cellular senescence not only is activated in primary cells, but can also be induced in tumor cells. Furthermore, there now is evidence that cellular senescence is also activated in vivo. Senescence markers were found in premalignant tumor lesions, and a close correlation could be drawn between inactivation of this pathway and the onset of tumor progression (Braig et al., 2005) . Thus, cellular senescence appears to be a potent mechanism suppressing early steps of tumor progression. Elucidation of the steps critical for arrest entrance and of the factors determining irreversibility of the senescent state is of utmost importance for the application of senescence induction in tumor therapy.
The tumor suppressor p53 has shown to be of primary importance for this growth arrest. Studies on primary mouse lymphomas revealed that tumors which escaped a drug-induced senescence program acquired mutations in the tumor suppressor genes p53 or ink4a (Schmitt et al., 2002) . Also, induction of a senescence program by loss of PTEN is abolished when p53 is nonfunctional (Chen et al., 2005) . Not only inactivation of p53 itself, but also of ARF, an alternative splice product of the ink4a locus, abrogates this response (Kamijo et al., 1997) . ARF blocks MDM2 mediated degradation of p53 and thereby stabilizes p53. Conversely, expression of exogenous p53 was capable to induce cellular senescence in p53 deficient tumor cells (Sugrue et al., 1997; Wang et al., 1998) .
Gene expression analysis of drug-induced senescence in tumor cells suggests that p53 mediates its growth suppressive functions in this arrest primarily by p21 CIP1 , a promiscuous inhibitor of cyclin-Cdk complexes (Chang et al., 2002) . This is consistent with p21
CIP1
representing the major transcriptional target of p53 in response to DNA damage and p21 CIP acting as the principal mediator of the p53 induced G1 arrest (elDeiry et al., 1993; Waldman et al., 1995) . Consistent with this, ectopic expression of p21 CIP1 in human p53
tumor cells resulted in a senescence phenotype (Bates et al., 1998) .
However, cellular senescence can also be activated in p21 À/À or p53 À/À tumor cells, although at a lower frequency (Chang et al., 1999) . Thus, additional factors contribute to this pathway. Studies on human cervix carcinoma cells provided evidence for a crosstalk between p53 and retinoblastoma proteins (Haupt et al., 1995; Psyrri et al., 2004) . In these cells, the functions of p53 and pRb/p105 are completely inactivated by the Human Papilloma Virus (HPV) oncogenes E6 and E7. When E6 and E7 were simultaneously repressed, restoring p53 and pRb/p105 to normal levels, cellular senescence was induced in up to 95% of the cells. When only p53 expression was restored, the proportion of senescent cells was drastically reduced. One thus can conclude that p53 on its own is not a very potent inducer of the senescent growth arrest, but requires crosstalk with retinoblastoma proteins.
The pRb/p105-mediated cell cycle arrest in cellular senescence
The pocket protein family consists of three members, pRb/p105, p107 and Rb2/p130. p107 and Rb2/p130 share homologies throughout the entire length of the protein, whereas their homology with pRb/p105 is limited to the conserved A/B-domains. The genes are located on different chromosomes and expression of the proteins is regulated differentially throughout the cell cycle (Lee et al., 1987; Hong et al., 1989; Mayol et al., 1993; Yeung et al., 1993; Baldi et al., 1996; Ichimura et al., 2000) . They associate with different E2F proteins, thereby blocking different subsets of gene promoters, but have in common that this interaction is regulated through phosphorylation by cyclin dependent kinases (Hurford et al., 1997; Classon et al., 2000) . The data suggest, that each of the retinoblastoma proteins has a certain, preferred function in cell cycle control, which may also affect their growth arrest functions in cellular senescence.
Studies on the repressor functions of retinoblastoma proteins in cellular senescence largely focus on pRb/ p105. Functions of pRb/p105 in the cell cycle are mainly determined by its phosphorylation status, as the protein level changes hardly (Buchkovich et al., 1989; Mihara et al., 1989) . pRb/p105 is only active as a growth repressor when present in its hypophosphorylated form (Chen et al., 1989) . pRb/p105 is minimally phosphorylated in G0 cells and is hyperphosphorylated in cycling cells. Cyclin D/ Cdk4 or 6 complexes phosphorylate pRb/p105 in early G1, while cyclin E/Cdk2 complexes phosphorylate pRb/ p105 in mid to late G1 phase ( Figure 1 ). Hyperphosphorylation continues through S phase by Cyclin A/ Cdk2 complexes until mitosis (Hinds et al., 1992; Dowdy et al., 1993; Lundberg and Weinberg, 1998) . After mitosis pRb/p105 again adopts its hypophosphorylated state, which is dependent on the activity of phosphoprotein phosphatase 1 (PP1) (Durfee et al., 1993; Ludlow et al., 1993) .
Cdk inhibitors such as p21 CIP1 or p16
INK4a
, which are functional in cellular senescence, block the cyclindependent kinases and shift pRb/p105 to the hypophosphorylated form. In G0 and early G1 pRb/p105 exerts its growth suppressive functions by sequestering the strong transcriptional activators E2F-1, -2, and -3 away from their promoters (Takahashi et al., 2000) or by forming repressor complexes at their promoter binding sites, containing the chromatin modulating factors histone deacetylase (HDAC) and BRG-1 . The pRb/p105 repressor complexes thereby efficiently impair the expression of S-phase genes: both, cyclin E and cyclin A promoters are repressed, showing that pRb/p105 stalls the cells prior to passage through the G1 restriction point .
The appearance of Cdk4 or 6 activity releases HDAC from the repressor complex and is sufficient to initiate exit from G1-into S-phase. This partial decay of the complex specifically relieves the cyclin E promoter from repression and stimulates the synthesis of cyclin E in a positive autoregulatory feed-back loop (Lundberg and Weinberg, 1998) . The remaining complex of pRb/p105 and BRG-1 still blocks the cyclin A promoter. Phosphorylation of pRb/p105 by cyclin E/Cdk2 complexes induce derepression of the cyclin A promoter and thereby initiate DNA synthesis .
The data indicate, that pRb/p105 can differentially regulate the expression of cyclin E and A. Inactivation or loss of Cdk inhibitors, which are required to block phosphorylation of pRb/p105 by cyclin D/Cdk4 or 6, is sufficient to release E2F1-3 transcription factors and to initiate S-phase (Bremner et al., 1995) . Accordingly, p16
, an inhibitor of Cdk4 and 6, was identified as a key regulator in cellular senescence (Beausejour et al., 2003) . Ectopic expression of p16
INK4a in p16
INK4aÀ/À tumor cells was shown to activate a senescence program, provided that the cells contained an intact pRb/p105 (Timmermann et al., 1998; Steiner et al., 2000) . However, not only the selective loss of pRb/p105 but also that of p107 and Rb2/p130 abolished the growth suppressive functions of p16
INK4a (Bruce et al., 2000) . Rodent cells lacking p16
INK4a or pRb/p105 entered INK4a . ARF blocks the ubiquitin ligase MDM2, and thereby stabilizes p53. p53 transactivates p21 CIP1 which blocks cyclin D and Cyclin E dependent Cdk activity; p16
INK4a inactivates Cdk4 or 6 and strengthens the arrest. This leads to an accumulation of hypophosphorylated pRb/p105, which stalls expression of cyclin E and cyclin A.
Regulation of cellular senescence by Rb2/p130
H Helmbold et al cellular senescence with the same efficiency as did the wild-type cells when transfected with an activated oncogene (Krimpenfort et al., 2001; Peeper et al., 2001; Sharpless et al., 2001) . In contrast, inactivation of p53 or ARF completely abolished the senescence response substantiating the key role of p53 in this pathway (Kamijo et al., 1997) . The data show that induction of cellular senescence not necessarily requires p16 INK4a or pRb/p105, but may also be based on functions of the other retinoblastoma proteins. There is evidence that Rb2/p130 instead of pRb/p105 can induce senescence in p16
INK4a negative cells (Kapic et al., 2006) .
The Rb2/p130-mediated growth arrest in cellular senescence
In contrast to pRb/p105, expression levels of Rb2/p130 change during the cell cycle. Rb2/p130 is the most abundant retinoblastoma protein in G0 (Kiess et al., 1995) , where it is already phosphorylated at unique sites by a not yet identified kinase (Canhoto et al., 2000) . Similar to pRb/p105, Rb2/p130 is hyperphosphorylated by cyclin D/Cdk4 or 6 and cyclin E or A/Cdk2 complexes. With entry of cells into S-phase, Rb2/p130 protein levels drop rapidly (Baldi et al., 1995; Mayol et al., 1995; Claudio et al., 1996; Dong et al., 1998) . Hyperphosphorylated Rb2/p130 associates with the protein-ubiquitin-ligase SCF(Skp2), is polyubiquitinated, and then subject to proteasomal degradation in late G1, which rapidly decreases its expression level in Sphase (Tedesco et al., 2002) . Thus, Rb2/p130 is removed completely when the cells adopt a proliferative status, leaving growth regulation in cycling cells to pRb/p105 or p107.
Different from pRb/p105, hypophosphorylated Rb2/ p130 binds to the poor transcriptional activators E2F-4, -5 and forms Rb2/E2F-4 repressor complexes together with HDACs at most E2F-responsive promoters (Smith et al., 1996; Ferreira et al., 1998; Stiegler et al., 1998; Iavarone and Massague, 1999; Takahashi et al., 2000; Macaluso et al., 2003; Liu et al., 2005) (Figure 2) . Likely, release from repression is initiated through Cterminal phosphorylation displacing HDAC (Stiegler et al., 1998; Harbour et al., 1999) . Subsequent hyperphosphorylation completely dissociates the Rb2/p130-E2F4 repressor complex from E2F-responsive promoters. Activator E2F proteins can then bind to their responsive promoters and restore histone acetylation by recruitment of HATs (Takahashi et al., 2000; Taubert et al., 2004) .
Functions of Rb2/p130 not only are relevant for the maintenance of a G0 arrest in quiescent or differentiated cells, but can also control transition from G1-to S- . p53 induces p21 CIP1 and blocks cyclin E dependent Cdk activity. This leads to increased levels of p27 KIP1 in an autoregulatory loop, which strengthens the arrest. Rb2/E2F-4 complexes block E2F-1 expression, which impairs the expression of p107 and pRb/p105. Repression of the cyclin A promoter by Rb2/ E2F-4 repressor complexes blocks progression into S-phase.
Regulation of cellular senescence by Rb2/p130 H Helmbold et al phase. For instance, overexpression of Rb2/p130 in three different cell lines (Saos-2, C33A, T98G) led to a G1 cell cycle arrest. Two of these cell lines did not respond with a G1 arrest when pRb/p105 was overexpressed (Hinds et al., 1992; Zhu et al., 1993; Claudio et al., 1994; Lacy and Whyte, 1997) .
Rb2/p130, a master regulator of retinoblastoma proteins in the sustained arrest Activation of p53, leading to a senescence arrest in p16
INK4a negative cells, raised the level of hypophosphorylated Rb2/p130 and concomitantly decreased those of pRb/p105 and p107. Levels of cyclin E, p27 KIP1 and p21 CIP1 increased, whereas cyclin A was repressed (Kapic et al., 2006) . A similar sequence of events was induced by overexpression of Rb2/p130 in JC virus-induced hamster brain tumor cells (Howard et al., 2000) .
Likely, p21 CIP1 plays a key role in this pathway by inhibiting the activity of cyclin D as well as cyclin E dependent kinases. This also increases the level of the Cdk inhibitor p27 KIP1 , which blocks the cyclin Eassociated kinase activity and consequently stabilizes Rb2/p130 in its hypophosphorylated form.
Expression of p27 KIP1 is regulated post-transcriptionally by cyclin E/Cdk2 dependent phosphorylation (Hengst and Reed, 1996) . Phosphorylation of p27 KIP1 at Thr187 promotes its binding to cyclin E/Cdk2, induces its ubiquitination and subsequent proteasomal degradation (Montagnoli et al., 1999; Nguyen et al., 1999) . Thus, the inhibitory functions of p27 KIP1 are tightly regulated by cyclin E/Cdk2. Elevated levels of p21 CIP1 , as they are induced by p53, block the activity of cyclin E/Cdk2 complexes, and thereby stabilize p27 KIP1 , which strengthens the sustained arrest (Alexander and Hinds, 2001) .
Hypophosphorylated Rb2/p130 forms strong repressor complexes with E2F-4, which block E2F-responsive promoter sites (Vairo et al., 1995; Iavarone and Massague, 1999; Takahashi et al., 2000) . It is of major importance that Rb2/p130 repressor complexes also bind to the E2F-1 promoter itself and thereby decrease the expression of this basal transcription factor (Hsiao et al., 1994; Johnson et al., 1994; Neuman et al., 1994; Smith et al., 1996; Takahashi et al., 2000; Araki et al., 2003) . E2F-1 sites within the E2F-1 promoter play a minor role in cycling cells but were shown to be essential for the maintenance of quiescence (Smith et al., 1996) . Thus, by blocking E2F-1 promoter sites and by decreasing the level of E2F-1, Rb2/p130 can impair expression of a large variety of cellular genes, among those pRb/p105 and p107 (Shan et al., 1994; Takahashi et al., 2000) .
The data indicate that Rb2/p130 can act as a master regulator of retinoblastoma proteins in a sustained arrest. Although not proven formally, this may also explain the decrease in p107 and pRb/105 expression subsequent to the appearance of Rb2/p130 in cellular senescence induced by p53 (Kapic et al., 2006) . Alternatively, p53 itself may block pRb/p105 expression via a p53 binding site in the pRb/p105 promoter (Shiio et al., 1992; Osifchin et al., 1994) .
Repression of cyclin A by Rb2/p130 is a critical step in Rb2-mediated senescence Arrested cells displaying a senescent phenotype can show elevated levels of cyclin E, but to lack cyclin A (Kapic et al., 2006) . It indicates that pRb/p105 is not functional in these cells, as cyclin E expression in G1/ S is primarily regulated by pRb/p105. In pRb/p105 À/À cells cyclin E is deregulated, reaching peak levels already in early G1 (Herrera et al., 1996; Lee et al., 2002) . As a result of the exclusive regulation of the cyclin E promoter by pRb/p105, levels of cyclin E increase concomitantly with the disappearance of this pocket protein.
Cyclin E expression is negatively regulated via an E2F binding site in the cyclin E promoter which recruits repressor complexes composed of pRb/p105, E2F1-3, HDAC, the histone methyltransferase Suv39H1 and HP1. pRb/p105 is absolutely necessary in this complex due to the specific requirement of E2F1-3 for promoter binding (Cobrinik, 2005) . A chromatin-remodeling machine was reported to be also involved in the regulation of the cyclin E promoter, claiming that the repressor complex consists of pRb/p105, HDAC and hBRM/BRG-1. Phosphorylation of pRb/p105 by cyclin D/Cdk4 disrupts the interaction with HDAC and relieves the cyclin E promoter from repression .
The presence of high amounts of cyclin E accumulating in arrested cells indicates that they are stalled beyond the restriction point in G1 (Pardee, 1989) . In this context, repression of cyclin A by Rb2/p130 turned out as the crucial step to prevent progression into S-phase in senescent cells (Kapic et al., 2006) .
Binding of Rb2/E2F-4 complexes to the cyclin A promoter has been observed in asynchronously growing and in serum-starved cells, as well as in senescent cells (Stiegler et al., 1998; Takahashi et al., 2000; Narita et al., 2003) . When Rb2/p130 expression is downregulated by E1A-12S or by Rb2/p130 siRNA, cyclin A expression increases and the cells proceed into S-phase (Kapic et al., 2006) . Thus, Rb2/p130 can block G1/S transition in a sustained arrest by specifically repressing cyclin A. Thereby cells, which have already over-run the G1 restriction point, are protected from entering the Sphase.
The factors responsible for the irreversibility of cellular senescence are of major concern. As reported, cells showing high levels of p16
INK4a in the senescence arrest, re-entered the cell cycle after pRb/p105 inactivation but did not proliferate. It has been suggested that proliferation is inefficiently restored due to high levels of p16
INK4a (Beausejour et al., 2003) . However, the same outcome could also be observed when cells lacking were released from the arrest upon inactivation of p53 (Kapic et al., 2006) . The finding suggests that, dependent on the cell type and the genetic background, p16
INK4a is not absolutely necessary to render the senescence arrest irreversible.
Recently, it has been proposed that binding of pRb/ p105 to the cyclin A promoter, which only takes place in senescent but not in quiescent cells, recruits histone methyltransferases to the promoter, and induces H3K9 methylation, HP1 recruitment and promoter silencing. The cyclin A promoter then is stably blocked such that it cannot be activated any more by E2F-1 . However, the data also indicate that large amounts of Rb2/p130 were bound to the cyclin A promoter, both in senescent and in quiescent cells. Thus, Rb2/p130 could well have an influence on cyclin A promoter activity in this system and maintain the senescent arrest by repressing cyclin A. Rb2/p130 can form a repressor complex similar to that formed by pRb/p105. It is known that Rb2/p130 by means of E2F-4 can recruit histone methyltransferases like Suv39H1 (Ghosh and Harter, 2003; Macaluso et al., 2003; Nicolas et al., 2003; Liu et al., 2005) and nucleosome remodeling machines such as hBRM/BRG-1 (Strober et al., 1996) that are necessary for an efficient repression of the cyclin A promoter (Strobeck et al., 2000; Coisy et al., 2004) . Possibly, recruitment of nucleosome remodeling machines to the cyclin A promoter is basic to induction of cellular senescence. Expression of an ectopic hBRM or BRG-1 in cells lacking these proteins is sufficient to induce a cell cycle arrest displaying a senescent phenotype (Dunaief et al., 1994; Strober et al., 1996; Zhang et al., 2000) . The phenotype is abolished when cells are transfected with an E1A construct, which inactivates retinoblastoma proteins (Dunaief et al., 1994; Strober et al., 1996) .
The available data suggest that Rb2/p130, due to its role as a master regulator of pocket protein expression in a sustained arrest, plays a key role in cellular senescence. Its strong repressor functions, based on association with E2F-4 transcription factors and chromatin remodeling proteins, predestine Rb2/p130 for this task. This role might also be important in tumor development. Low levels of Rb2/p130 expression in primary tumors correlate with a high malignancy (Baldi et al., 1997; Susini et al., 2001; Li et al., 2004) . One would expect that decreased levels of Rb2/p130 observed in strongly proliferating tumor cells simply result from decreased protein stability as is the case in normally cycling cells (Tedesco et al., 2002) . However, Rb2/p130 in tumors seemed to be downregulated at the transcriptional level and not by posttranslational modifications (Milde-Langosch et al., 2001; D'Andrilli et al., 2004) . Therefore, deregulation of Rb2/p130 expression could well be an important event in development and/or progression of tumors by impairing the onset of the senescence program.
